Skip to main content
Equibles
APVO logo

APVO · Aptevo Therapeutics Inc. · Metrics

Track APVO — free

Use APVO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APVO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.80 +0.04 (+2.27%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$3.39M
Shares
1.80M
Volume · Oct 5 28.1K Avg daily vol (3M) 111.65K

APVO metrics

50 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.76
Market cap
$3.39M

Price action

20 metrics
Price change (1W)
-6.9%
Price change (30D)
-6.4%
Price change (3M)
-60.6%
Price change (6M)
-57.8%
Price change (YTD)
-81.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
87.4%
Annualized volatility (3M)
101.6%
Beta
0.8
RSI (14D)
32.8
Price vs SMA 50
-34.8%
Price vs SMA 200
—
Avg volume (3M)
111,654
Relative volume
0.1
Average dollar volume
$305,866

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.80M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 92,847.2%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 383.3%
P / book
0.6
reciprocal yield 178.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-779.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-919.7%
Trailing 12 months
Net margin
257.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$26.89M
Net income (TTM)
−$26.41M
Trailing 12 months
Diluted EPS (TTM)
$1,634.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.42

Growth

11 metrics
Revenue growth YoY
+28.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.98M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,817.4%
Year over year · more shares
Revenue CAGR (3Y)
-54.2%
Revenue CAGR (5Y)
-26.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-437.1%
Return on assets
-181.9%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$26.69M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$9.80M
Total assets
$14.52M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.34M
Capital expenditures (TTM)
—
R&D (TTM)
$15.20M
SG&A (TTM)
$25.34M
Stock compensation (TTM)
$194,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
9
13F filer change QoQ
0
Institutional ownership
2.8%

Short interest

3 metrics
Short interest
10.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1671584 CUSIP 03835L702 Visit website Investor relations